An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2

Monoclonal antibodies targeting the SARS-CoV-2 spike (S) glycoprotein neutralize infection and are efficacious for the treatment of mild-to-moderate COVID-19. However, SARS-CoV-2 variants have emerged that partially or fully escape monoclonal antibodies in clinical use. Notably, the BA.2 sublineage...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lianghui, Narayanan, Krishna K., Cooper, Laura, Chan, Kui K., Devlin, Christine A., Aguhob, Aaron, Shirley, Kristie, Rong, Lijun, Rehman, Jalees, Malik, Asrar B., Procko, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978935/
https://www.ncbi.nlm.nih.gov/pubmed/35378764
http://dx.doi.org/10.1101/2022.03.28.486075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978935/
https://www.ncbi.nlm.nih.gov/pubmed/35378764
http://dx.doi.org/10.1101/2022.03.28.486075

Ejemplares similares